Devastating 10-K: Skye Bioscience Reports $55.9M Net Loss, $1.41 EPS
Summary
Skye Bioscience reported a substantial net loss of $55.9 million, or $1.41 per share, for the year ended December 31, 2025, as detailed in its 10-K filing. This significant loss, driven by ongoing R&D and administrative costs, is more than double the company's current market capitalization. While a recent SEC 10-K filing (on the same day) already indicated a critical financial state with a going concern warning and NASDAQ delisting risk, these specific figures quantify the severe financial instability. The unsustainable burn rate relative to its valuation poses an immediate threat to the company's operational runway and long-term viability. Traders will be closely watching for any further capital raises or strategic shifts to address this critical financial position.
At the time of this announcement, SKYE was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.6M. The 52-week trading range was $0.68 to $5.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.